Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | exodeoxyribonuclease III family protein | 0.0021 | 0.0235 | 0.0959 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0225 | 0.432 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0.0235 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.0168 | 0.0687 |
Onchocerca volvulus | 0.0015 | 0.0126 | 0.5 | |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0015 | 0.0126 | 0.0126 |
Onchocerca volvulus | 0.0015 | 0.0126 | 0.5 | |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0225 | 0.432 | 1 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0017 | 0.0168 | 0.0687 |
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 0.0918 | 0.375 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0017 | 0.0168 | 0.0168 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0055 | 0.0918 | 0.375 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0225 | 0.432 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0015 | 0.0126 | 0.0513 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0225 | 0.432 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0.0235 | 0.0261 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0.0235 | 0.0261 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0235 | 0.4114 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.0168 | 0.2944 |
Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0126 | 0.0513 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0235 | 0.0261 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0131 | 0.2449 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0235 | 0.0261 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.0168 | 0.2944 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0.0235 | 0.0261 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0225 | 0.432 | 1 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0015 | 0.0126 | 0.22 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0.0235 | 0.0261 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0017 | 0.0168 | 0.0687 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 0.0235 | 0.0235 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0131 | 0.2449 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0017 | 0.0168 | 0.0168 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.0168 | 0.2944 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0015 | 0.0126 | 0.0513 |
Brugia malayi | MH2 domain containing protein | 0.0131 | 0.2449 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0225 | 0.432 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0017 | 0.0168 | 0.0687 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0.0235 | 1 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0015 | 0.0126 | 0.0513 |
Schistosoma mansoni | dihydropteridine reductase | 0.0015 | 0.0126 | 0.22 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0017 | 0.0168 | 0.0168 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0235 | 0.4114 |
Schistosoma mansoni | hypothetical protein | 0.0037 | 0.0571 | 1 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0225 | 0.432 | 1 |
Echinococcus multilocularis | neuropeptide receptor A26 | 0.0508 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.0168 | 0.2944 |
Echinococcus multilocularis | neuropeptide s receptor | 0.0508 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0235 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0.0235 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0015 | 0.0126 | 0.0513 |
Echinococcus granulosus | neuropeptide receptor A26 | 0.0508 | 1 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.0225 | 0.432 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0.0235 | 0.5 |
Echinococcus multilocularis | GPCR, family 2 | 0.0017 | 0.0168 | 0.0168 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0037 | 0.0571 | 0.2332 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0.0235 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.0571 | 0.2332 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0015 | 0.0126 | 0.0513 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0055 | 0.0918 | 0.375 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0015 | 0.0126 | 0.0126 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0017 | 0.0168 | 0.0168 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0225 | 0.432 | 1 |
Echinococcus granulosus | GPCR family 2 | 0.0017 | 0.0168 | 0.0168 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0055 | 0.0918 | 0.375 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 0.0235 | 0.0959 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 0.0235 | 0.0235 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0235 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.